PL2726880T3 - Leczenie nowotworu prostaty i sposób określania prognozy dla pacjentów z nowotworem prostaty - Google Patents

Leczenie nowotworu prostaty i sposób określania prognozy dla pacjentów z nowotworem prostaty

Info

Publication number
PL2726880T3
PL2726880T3 PL12807837T PL12807837T PL2726880T3 PL 2726880 T3 PL2726880 T3 PL 2726880T3 PL 12807837 T PL12807837 T PL 12807837T PL 12807837 T PL12807837 T PL 12807837T PL 2726880 T3 PL2726880 T3 PL 2726880T3
Authority
PL
Poland
Prior art keywords
prostate cancer
forecast
patients
treatment
prostate
Prior art date
Application number
PL12807837T
Other languages
English (en)
Inventor
Tommy Andersson
Anders BJARTELL
Original Assignee
Wntresearch Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wntresearch Ab filed Critical Wntresearch Ab
Publication of PL2726880T3 publication Critical patent/PL2726880T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL12807837T 2011-07-01 2012-06-28 Leczenie nowotworu prostaty i sposób określania prognozy dla pacjentów z nowotworem prostaty PL2726880T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1150619 2011-07-01
EP12807837.5A EP2726880B1 (en) 2011-07-01 2012-06-28 Treatment of prostate cancer and a method for determining the prognosis for prostate cancer patients
PCT/SE2012/050738 WO2013006129A1 (en) 2011-07-01 2012-06-28 Treatment of prostate cancer and a method for determining the prognosis for prostate cancer patients

Publications (1)

Publication Number Publication Date
PL2726880T3 true PL2726880T3 (pl) 2019-09-30

Family

ID=47437285

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12807837T PL2726880T3 (pl) 2011-07-01 2012-06-28 Leczenie nowotworu prostaty i sposób określania prognozy dla pacjentów z nowotworem prostaty

Country Status (8)

Country Link
US (1) US9278119B2 (pl)
EP (1) EP2726880B1 (pl)
DK (1) DK2726880T3 (pl)
ES (1) ES2735540T3 (pl)
HU (1) HUE045368T2 (pl)
PL (1) PL2726880T3 (pl)
TR (1) TR201910508T4 (pl)
WO (1) WO2013006129A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3229831B1 (en) * 2014-12-10 2020-03-11 Hyperstem SA Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brain tumors
WO2019081657A1 (en) * 2017-10-25 2019-05-02 Wntresearch Ab WNT5A PEPTIDES FOR REDUCING CANCER STEM CELLS
WO2020053200A1 (en) * 2018-09-10 2020-03-19 Wntresearch Ab Peptides for use in treatment of psoriasis
CN113939305A (zh) * 2019-04-16 2022-01-14 温特研究公司 用于治疗癌症的与免疫检查点抑制剂组合的肽

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601363B1 (fr) 1986-07-08 1988-10-21 Synthelabo (dimethylamino)-2 ethyl) ((((methylthio)-2 phenyl) (phenylmethyl)amino)-2 oxo-2 ethyl) carbamates ou urees, leur preparation et leur application en therapeutique.
AU5369498A (en) * 1996-11-27 1998-06-22 Penn State Research Foundation, The Compounds and methods for treating cancer
AU2030000A (en) 1998-11-25 2000-06-13 Cadus Pharmaceutical Corporation Methods and compositions for identifying receptor effectors
EP1033405A3 (en) 1999-02-25 2001-08-01 Ceres Incorporated Sequence-determined DNA fragments and corresponding polypeptides encoded thereby
AU1700700A (en) 1999-11-05 2001-05-14 Forskarpatent I Syd Ab Compounds, antibodies and methods for treating, preventing or diagnosing tumour metastasis
MXPA02005596A (es) 1999-12-07 2004-09-10 Theravance Inc Derivados de carbamato con actividad antagonista para el rerceptor muscarinico.
US7247426B2 (en) 2001-08-02 2007-07-24 Agilent Technologies, Inc. Classifying cancers
CA2500687A1 (en) 2002-10-02 2004-04-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2384763B1 (en) 2005-05-30 2015-04-29 Wntresearch AB A peptide ligand to impair cancer cell migration
US20110124574A1 (en) * 2008-04-30 2011-05-26 Tommy Andersson Restoration of estrogen receptor-(alpha) activity
AU2009282525A1 (en) 2008-08-13 2010-02-18 Wntresearch Ab The use of Wnt5-a peptide derivates for the treatment of melanoma and gastric cancer
WO2012109540A1 (en) * 2011-02-10 2012-08-16 Fox Chase Cancer Center Methods for inducing epithelial cancer cell senescence

Also Published As

Publication number Publication date
EP2726880A4 (en) 2015-03-04
DK2726880T3 (da) 2019-07-15
EP2726880A1 (en) 2014-05-07
US20140206623A1 (en) 2014-07-24
US9278119B2 (en) 2016-03-08
EP2726880B1 (en) 2019-04-17
WO2013006129A1 (en) 2013-01-10
HUE045368T2 (hu) 2019-12-30
ES2735540T3 (es) 2019-12-19
TR201910508T4 (tr) 2019-08-21

Similar Documents

Publication Publication Date Title
IL224370B (en) Combination treatment for prostate carcinoma
SI2619576T1 (sl) Sredstva in metode za predvidevanje odziva rakavega pacienta na zdravljenje
PL2780036T3 (pl) Kompozycje nanocząstek do generowania regulatorowych komórek t i leczenie chorób autoimmunologicznych i innych przewlekłych stanów zapalnych
IL228538A0 (en) Methods for increasing efficacy of folr1 cancer therapy
LT3354747T (lt) Neinvazinis naviko metilomos nustatymas iš plazmos
HRP20160714T1 (hr) Sredstva za induciranje apoptoze namijenjena liječenju raka i imunih i autoimunih bolesti
HUE048876T2 (hu) Rákos megbetegedések kezelése
PL2739153T3 (pl) Leczenie raka sutka
BR112014001440A2 (pt) novas composições e métodos para o tratamento de câncer de próstata
IL237592B (en) Methods of expanding and assessing b cells and using expanded b cells to treat disease
PL2553642T3 (pl) Sposoby i układy do weryfikacji transakcji
PL2552438T3 (pl) Sposoby leczenia raka wątrobowokomórkowego
IL243408A0 (en) Diagnosis and therapy of cancer involving cancer stem cells
IL232517A0 (en) Treatment of hematologic malignancies with an anti-cxcr4 antibody
PL2544682T3 (pl) Fitokannabinoidy w leczeniu glejaka
EP2761554A4 (en) PAYMENTS IN SOCIAL PROXIMITY
PL2681333T3 (pl) Ewaluacja odpowiedzi na leczenie endokrynnych nowotworów żołądkowo-trzustkowo-jelitowych (gep-nen)
IL239007B (en) Eribulin for use in the treatment of breast cancer
HRP20181462T1 (hr) Kombinacija regorafeniba i acetilsalicilne kiseline za liječenje raka debelog crijeva
EP2920308A4 (en) CANCER TREATMENT
PL2830654T3 (pl) Sposoby i kompozycje do leczenia zapalenia
EP2911193A4 (en) COOLING STRUCTURE AND HEAT-GENERATING BODY
HRP20182043T8 (hr) Upotreba anti-koneksinskih sredstava za poboljšanje terapijskog učinka inhibitora acetilkolinesteraze
PL2552484T3 (pl) Sposoby i preparaty służące do zmniejszenia poziomu hormonu przytarczyc
IL226246A0 (en) Methods of treating cancer